Morphine‐6‐glucuronide: Actions and mechanisms
- 10 June 2005
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 25 (5), 521-544
- https://doi.org/10.1002/med.20035
Abstract
Morphine‐6‐glucuronide (M6G) appears to show equivalent analgesia to morphine but to have a superior side‐effect profile in terms of reduced liability to induce nausea and vomiting and respiratory depression. The purpose of this review is to examine the evidence behind this statement and to identify the possible reasons that may contribute to the profile of M6G. The vast majority of available data supports the notion that both M6G and morphine mediate their effects by activating the µ‐opioid receptor. The differences for which there is a reasonable consensus in the literature can be summarized as: (1) Morphine has a slightly higher affinity for the µ‐opioid receptor than M6G, (2) M6G shows a slightly higher efficacy at the µ‐opioid receptor, (3) M6G has a lower affinity for the κ‐opioid receptor than morphine, and (4) M6G has a very different absorption, distribution, metabolism, and excretion (ADME) profile from morphine. However, none of these are adequate alone to explain the clinical differences between M6G and morphine. The ADME differences are perhaps most likely to explain some of the differences but seem unlikely to be the whole story. Further work is required to examine further the profile of M6G, notably whether M6G penetrates differentially to areas of the brain involved in pain and those involved in nausea, vomiting, and respiratory control or whether µ‐opioid receptors in these brain areas differ in either their regulation or pharmacology. © 2005 Wiley Periodicals, Inc. Med Res RevKeywords
This publication has 153 references indexed in Scilit:
- Insights into mu opioid pharmacology: The role of mu opioid receptor subtypesLife Sciences, 2001
- Antinociceptive effects of morphne-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wildtype mice in the hotplate testLife Sciences, 2000
- Novel receptor mechanisms for heroin and morphine-6β-glucuronide analgesiaNeuroscience Letters, 1996
- the apparent affinity of morphine-3-glucuronide at μ1-opioid receptors results from morphine contamination: demonstration using HPLC and radioligand bindingLife Sciences, 1995
- Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypesLife Sciences, 1995
- The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complexLife Sciences, 1994
- Morphine-6-glucoronide: A potent stimulator of locomotor activity in miceLife Sciences, 1994
- Morphine Pharmacokinetics and Metabolism in HumansClinical Pharmacokinetics, 1993
- Species difference of site-selective glucuronidation of morphine.Journal of Pharmacobio-Dynamics, 1991
- Morphine-6-glucuronide: Analgesic effects and receptor binding profile in ratsLife Sciences, 1988